Loading...

Global Pharmaceutical R&D Demand Will Unlock Future Value

Published
04 May 25
Updated
27 Aug 25
AnalystConsensusTarget's Fair Value
CN¥113.31
15.6% undervalued intrinsic discount
27 Aug
CN¥95.69
Loading
1Y
147.2%
7D
4.4%

Author's Valuation

CN¥113.3

15.6% undervalued intrinsic discount

AnalystConsensusTarget Fair Value

Shared on25 Aug 25
Fair value Increased 6.40%

The upward revision in WuXi AppTec's consensus Analyst Price Target reflects increased optimism driven by a notable rise in both future P/E and net profit margin, raising the fair value estimate from CN¥106.50 to CN¥112.51. What's in the News Completed HKD 7.70 billion follow-on equity offering, issuing 73.8 million H shares at HKD 104.27 per share through a subsequent direct listing.

Shared on31 Jul 25

With both future P/E and net profit margin showing only marginal changes, analysts have left their fair value estimate for WuXi AppTec unchanged at CN¥106.50. What's in the News WuXi AppTec filed a follow-on equity offering of 73,800,000 H Shares via a subsequent direct listing.